Literature DB >> 30024859

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Radwa Sharaf1,2, Guinevere Q Lee3, Xiaoming Sun3, Behzad Etemad1, Layla M Aboukhater1, Zixin Hu1, Zabrina L Brumme4,5, Evgenia Aga6, Ronald J Bosch6, Ying Wen1, Golnaz Namazi1, Ce Gao3, Edward P Acosta7, Rajesh T Gandhi3,8, Jeffrey M Jacobson9, Daniel Skiest10, David M Margolis11, Ronald Mitsuyasu12, Paul Volberding13, Elizabeth Connick14, Daniel R Kuritzkes1, Michael M Lederman15, Xu G Yu3,7, Mathias Lichterfeld1,3, Jonathan Z Li1.   

Abstract

HIV posttreatment controllers (PTCs) represent a natural model of sustained HIV remission, but they are rare and little is known about their viral reservoir. We obtained 1,450 proviral sequences after near-full-length amplification for 10 PTCs and 16 posttreatment noncontrollers (NCs). Before treatment interruption, the median intact and total reservoir size in PTCs was 7-fold lower than in NCs, but the proportion of intact, defective, and total clonally expanded proviral genomes was not significantly different between the 2 groups. Quantification of total but not intact proviral genome copies predicted sustained HIV remission as 81% of NCs, but none of the PTCs had a total proviral genome greater than 4 copies per million peripheral blood mononuclear cells (PBMCs). The results highlight the restricted intact and defective HIV reservoir in PTCs and suggest that total proviral genome burden could act as the first biomarker for identifying PTCs. Total and defective but not intact proviral copy numbers correlated with levels of cell-associated HIV RNA, activated NK cell percentages, and both HIV-specific CD4+ and CD8+ responses. These results support the concept that defective HIV genomes can lead to viral antigen production and interact with both the innate and adaptive immune systems.

Entities:  

Keywords:  AIDS vaccine; AIDS/HIV; Infectious disease

Mesh:

Substances:

Year:  2018        PMID: 30024859      PMCID: PMC6118642          DOI: 10.1172/JCI120549

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  How often does treatment of primary HIV lead to post-treatment control?

Authors:  Janine Maenza; Kenneth Tapia; Sarah Holte; Joanne D Stekler; Claire E Stevens; James I Mullins; Ann C Collier
Journal:  Antivir Ther       Date:  2015-04-23

2.  Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells.

Authors:  Guinevere Q Lee; Nina Orlova-Fink; Kevin Einkauf; Fatema Z Chowdhury; Xiaoming Sun; Sean Harrington; Hsiao-Hsuan Kuo; Stephane Hua; Hsiao-Rong Chen; Zhengyu Ouyang; Kavidha Reddy; Krista Dong; Thumbi Ndung'u; Bruce D Walker; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

3.  Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.

Authors:  Bin Li; Adrianne D Gladden; Marcus Altfeld; John M Kaldor; David A Cooper; Anthony D Kelleher; Todd M Allen
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.

Authors:  Lambert Assoumou; Laurence Weiss; Christophe Piketty; Marianne Burgard; Adeline Melard; Pierre-Marie Girard; Christine Rouzioux; Dominique Costagliola
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

5.  Effect of polypurine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity.

Authors:  Lesa R Miles; Beth E Agresta; Mahfuz B Khan; Shixing Tang; Judith G Levin; Michael D Powell
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

8.  Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.

Authors:  Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

9.  Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation.

Authors:  Mila Jankovic; Michel C Nussenzweig; Lillian B Cohn; Israel T da Silva; Renan Valieris; Amy S Huang; Julio C C Lorenzi; Yehuda Z Cohen; Joy A Pai; Allison L Butler; Marina Caskey
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

10.  HIV-1 DNA predicts disease progression and post-treatment virological control.

Authors:  James P Williams; Jacob Hurst; Wolfgang Stöhr; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Mary Carrington; Abdel Babiker; Jonathan Weber; Kersten K Koelsch; Anthony D Kelleher; Rodney E Phillips; John Frater
Journal:  Elife       Date:  2014-09-12       Impact factor: 8.140

View more
  33 in total

1.  Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.

Authors:  Zachary Strongin; Luca Micci; Rémi Fromentin; Justin Harper; Julia McBrien; Emily Ryan; Neeta Shenvi; Kirk Easley; Nicolas Chomont; Guido Silvestri; Mirko Paiardini
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

2.  Long-term remission despite clonal expansion of replication-competent HIV-1 isolates.

Authors:  Rebecca T Veenhuis; Abena K Kwaa; Caroline C Garliss; Rachel Latanich; Maria Salgado; Christopher W Pohlmeyer; Christopher L Nobles; John Gregg; Eileen P Scully; Justin R Bailey; Frederic D Bushman; Joel N Blankson
Journal:  JCI Insight       Date:  2018-09-20

Review 3.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 4.  On the Road to a HIV Cure: Moving Beyond Berlin and London.

Authors:  Nikolaus Jilg; Jonathan Z Li
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

Review 5.  Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.

Authors:  Leila B Giron; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-19       Impact factor: 5.071

6.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.

Authors:  Alexander O Pasternak; Marlous L Grijsen; Ferdinand W Wit; Margreet Bakker; Suzanne Jurriaans; Jan M Prins; Ben Berkhout
Journal:  JCI Insight       Date:  2020-03-26

8.  Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy.

Authors:  Annukka Ar Antar; Katharine M Jenike; Sunyoung Jang; Danielle N Rigau; Daniel B Reeves; Rebecca Hoh; Melissa R Krone; Jeanne C Keruly; Richard D Moore; Joshua T Schiffer; Bareng As Nonyane; Frederick M Hecht; Steven G Deeks; Janet D Siliciano; Ya-Chi Ho; Robert F Siliciano
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 9.  Challenges and Promise of Human Immunodeficiency Virus Remission.

Authors:  Yijia Li; Abbas Mohammadi; Jonathan Z Li
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

Review 10.  Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges.

Authors:  Kristine E Yoder; Anthony J Rabe; Richard Fishel; Ross C Larue
Journal:  Front Mol Biosci       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.